The Global Landscape on the Access to Cancer Medicines for Breast Cancer: The ONCOLLEGE Experience.
| Autor: | Lengyel CG; Head and Neck Surgery, National Institute of Oncology Hungary, 1122, Budapest, Hungary. lengyel.csongor@gmail.com., Habeeb BS; Department of Medical Oncology, Shaqlawa Teaching Hospital, Shaqlawa, Erbil, 44005, Iraq., Altuna SC; Medical Oncology Department, Oncomédica C.A, Caracas, 1010, Venezuela., Trapani D; Department of Oncology and Hematology, University of Milan, 20122, Milan, Italy., Khan SZ; Department of Clinical Oncology, Bannu Institute of Nuclear Medicine Oncology and Radiotherapy (BINOR), Bannu, Khyber Pakhtunkhwa, Pakistan., Hussain S; Leicester Royal Infirmary, University Hospitals of Leicester, Leicester, LE1 5WW, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cancer treatment and research [Cancer Treat Res] 2023; Vol. 188, pp. 353-368. |
| DOI: | 10.1007/978-3-031-33602-7_14 |
| Abstrakt: | There is a growing global debate over barriers affecting the timely access to innovative anticancer therapies. Access to medicines is often traced back to the issue of costs: however, more commonly, the distance between valuable innovative treatments and the actual treatment of patients is far beyond the mere problem of financial barriers. A comprehensive approach to understand, assess to medicines should be pursued, to dissect the determinants and formulate solutions for all patients. In this chapter, we discuss drivers of access to innovation for patients with breast cancer, based on a case study of access to HER2-diagnositcs and therapeutics yielding a global landscape analysis, based on the efforts and expertise of the global collaborative group "ONCOLLEGE". (© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|